ArticleJournal of thoracic disease2026
Association between statins and chronic obstructive pulmonary disease: insights from cohort and genetic validation.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic obstructive pulmonary disease (COPD) is a leading cause of all-cause mortality, frequently accompanied by comorbidities such as cardiovascular disease and diabetes. Statins, commonly prescribed for hyperlipidemia, also exhibit anti-inflammatory properties that may benefit patients with COPD. This study aimed to evaluate the impact of statin utilization on all-cause mortality among COPD patients with data from the National Health and Nutrition Examination Survey (NHANES) and applying Mendelian randomization (MR) analysis to explore potential causal associations. Methods: This study obtained data using the NHANES (2007-2018) database, which contained information on COPD patients with active statin prescriptions and the associated mortality data. All-cause mortality was defined as the primary outcome in this study. Cox regression models were used to determine the association between statin use and mortality, adjusting for demographic and clinical variables. MR analysis, leveraging genetic variants associated with statin use, was employed to assess potential causality. Results: In the study of 2,416 COPD patients, the use of statins was linked to a 41% decrease in all-cause mortality [hazard ratio (HR) =0.59, 95% confidence interval (CI): 0.36-0.98]. Mediation analysis further revealed that C-reactive protein (CRP) partially mediated the protective effect of statins on all-cause mortality in COPD patients, accounting for 5.5% of the total effect. MR analysis indicated that statin use was associated with a 17% decrease in the risk of COPD (OR =0.83, 95% CI: 0.78-0.90). Conclusions: Statins may reduce all-cause mortality in COPD patients, indicating potential therapeutic benefits beyond cholesterol management. Nonetheless, further research is needed to confirm these results.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.